Mad Money Mailbag: High Price to Pay for Bard

Editor's note: The following are questions received from viewers of "Mad Money," seen every day at 6 p.m. EST on CNBC.

I bought C.R. Bard (BCR) a couple of points ago. Do you have a positive outlook for the stock?-- Tony from Illinois

James J. Cramer:

I believe this is a great medical devices company, though the stock appears somewhat expensive. At around $64 a share, Bard is trading at 21 times earnings, compared with just 15% annual growth potential.

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by

clicking here

.